福安藥業(300194.SZ):只楚藥業收到注射用伏立康唑的藥品註冊證書
格隆匯7月24日丨福安藥業(300194.SZ)公佈,公司全資子公司福安藥業集團煙台只楚藥業有限公司(簡稱“只楚藥業”)於近日收到國家藥品監督管理局簽發的藥品註冊證書,為注射用伏立康唑。
注射用伏立康唑是一種廣譜的三唑類抗真菌藥,主要適用於治療成人和2歲及2歲以上兒童患者的真菌感染。根據國家藥品監督管理局數據查詢信息平台顯示,截止目前,該藥品已有18家企業(含只楚藥業)通過一致性評價或視同通過一致性評價。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.